Calixa Therapeutics
San Mateo
About Calixa Therapeutics
Calixa Therapeutics, Inc. is a privately-held biopharmaceutical company focused on the development of a novel cephalosporin to address the expanding problem of multi-drug resistant organisms. Treatment of infections caused by resistant gram-negative bacteria, especially Pseudomonas aeruginosa, is recognized as an unmet medical need by the infectious diseases community. Calixa’s lead product, CXA-101, is an IV formulation of a novel cephalosporin that has excellent potency especially against multi-drug resistant Pseudomonas aeruginosa, which differentiates it from other cephalosporins. No similar drug is known to be in development. Calixa plans to combine this product with a IJ-lactamase inhibitor; the combination product (CXA-201) has the potential to become the first-line therapeutic choice for hospitalized patients suffering from serious infection caused by gram-negative organisms.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Funding stage: M&A
- Last round: Undisclosed (Jan 2007)
- Website: calixainc.com
- Phone: 858-480-2420
Industries & Categories
Biotechnology
Canonical: https://fsome.com/organization/calixa-therapeutics-2264046 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.